New Blood Test Shows Promise in Predicting Melanoma Recurrence Risk
A new study from the COMBI-AD trial shows that circulating tumour DNA (ctDNA) testing can accurately predict recurrence and survival in stage III melanoma, offering a potential tool for personalising treatment.